A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUNDS: The development of several types of vaccines to avert COVID-19 has taken place. Despite several reports of undesirable reactions noted post-COVID-19 vaccine administration, later remains one of the best prevention and management tools in fighting the spread of the virus and its variants and reducing the harshness of this viral attack. The purpose of the current paper was to explore the side-effects experienced by the females in the Eastern Province of Saudi Arabia directly after receiving the booster dose of the Pfizer-BioNTech/BNT162b2 COVID-19 vaccine.
METHODS: A descriptive cross-sectional study among adults living in the East-ern Province, Saudi Arabia was applied. A survey link was, distributed through WhatsApp, SMS, or e-mail to community members. Respondent's demographic information was acquired, as well as information about any local and systemic side-effects reported following booster dose of BioNTech/BNT162b2 COVID-19 vaccine.
RESULTS: A total of 72.36% (432/597) of the respondents who participated in this study reported at least one side-effect. Pain and redness at the injection site (75.93%), myalgia (71.99%), headache (53.24%), fever (33.56%), and fatigue (43.78%) were the highest frequently stated side-effects. Furthermore, 9.25% of the respondents had to see a physician due to side effects, plus merely four participants were admitted to the hospital. The respondents working in the non-healthcare-related sector had a 1.677-fold more possibility of side effects in comparison with the other respondents (adjusted odds ratio = 1.677; 95% CI = 1.363, 2.064).
CONCLUSIONS: All reported side-effects were mild to moderate. These findings might persuade pessimists and refusers to get the COVID-19 vaccine. Myalgia and pain or redness at the site of injection were the most common reported side-effects in our study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Vaccine - 40(2022), 49 vom: 22. Nov., Seite 7087-7096 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hassan, Yousif A M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 28.11.2022 Date Revised 26.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2022.10.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349176302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349176302 | ||
| 003 | DE-627 | ||
| 005 | 20231226042011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2022.10.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349176302 | ||
| 035 | |a (NLM)36404426 | ||
| 035 | |a (PII)S0264-410X(22)01257-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hassan, Yousif A M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2022 | ||
| 500 | |a Date Revised 26.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUNDS: The development of several types of vaccines to avert COVID-19 has taken place. Despite several reports of undesirable reactions noted post-COVID-19 vaccine administration, later remains one of the best prevention and management tools in fighting the spread of the virus and its variants and reducing the harshness of this viral attack. The purpose of the current paper was to explore the side-effects experienced by the females in the Eastern Province of Saudi Arabia directly after receiving the booster dose of the Pfizer-BioNTech/BNT162b2 COVID-19 vaccine | ||
| 520 | |a METHODS: A descriptive cross-sectional study among adults living in the East-ern Province, Saudi Arabia was applied. A survey link was, distributed through WhatsApp, SMS, or e-mail to community members. Respondent's demographic information was acquired, as well as information about any local and systemic side-effects reported following booster dose of BioNTech/BNT162b2 COVID-19 vaccine | ||
| 520 | |a RESULTS: A total of 72.36% (432/597) of the respondents who participated in this study reported at least one side-effect. Pain and redness at the injection site (75.93%), myalgia (71.99%), headache (53.24%), fever (33.56%), and fatigue (43.78%) were the highest frequently stated side-effects. Furthermore, 9.25% of the respondents had to see a physician due to side effects, plus merely four participants were admitted to the hospital. The respondents working in the non-healthcare-related sector had a 1.677-fold more possibility of side effects in comparison with the other respondents (adjusted odds ratio = 1.677; 95% CI = 1.363, 2.064) | ||
| 520 | |a CONCLUSIONS: All reported side-effects were mild to moderate. These findings might persuade pessimists and refusers to get the COVID-19 vaccine. Myalgia and pain or redness at the site of injection were the most common reported side-effects in our study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Booster dose | |
| 650 | 4 | |a COVID‐19 vaccine | |
| 650 | 4 | |a Eastern Province | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Saudi Arabia | |
| 650 | 4 | |a Side‐Effects | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Daud Ali, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Eid, Rawan Rashad |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ghuraya, Fatimah Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Essa Alqasimi, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Ayaz |e verfasserin |4 aut | |
| 700 | 1 | |a Eltrafi, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Sherihan Ahmad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 40(2022), 49 vom: 22. Nov., Seite 7087-7096 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:49 |g day:22 |g month:11 |g pages:7087-7096 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2022.10.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 49 |b 22 |c 11 |h 7087-7096 | ||